학술논문
Efficacy and safety of brigimadlin (BI 907828), an MDM2–p53 antagonist, in patients (pts) with advanced biliary tract cancer: Data from two phase Ia/Ib dose-escalation/expansion trials.
Document Type
Article
Author
Source
Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p487-487, 151p
Subject
Language
ISSN
0732183X